QLT initiates phase II study of punctal plug drug delivery system for glaucoma & ocular hypertension
"I believe that a punctal plug drug delivery system could be a catalyst for a paradigm shift in how glaucoma is treated and this clinical study is a critical first step in evaluating a component of this system, and it's potential to help patients manage their disease. If successful, these plugs could eliminate the patient's dosing dependency and possibly provide consistent 24-hour control for intraocular pressure (IOP). Our goal in 2008 is to deliver drug in a punctal plug delivery system to glaucoma patients for periods of approximately 90 days, with the aim of leading to a therapeutic drop in IOP," said Bob Butchofsky, President and Chief Executive Officer of QLT.
This study is a phase II, randomized, masked, parallel-group study of safety and preliminary efficacy of a punctal plug drug delivery system involving up to 60 patients with primary open-angle glaucoma or ocular hypertension. The punctal plug drug delivery system in this study consists of three different concentrations of latanoprost, a prostaglandin analogue.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.